4.6 Review

Targeted therapy for advanced esophagogastric adenocarcinoma

期刊

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 90, 期 1, 页码 68-76

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2013.10.004

关键词

Gastric cancer; Esophageal cancer; Targeted therapy; HER2; EGFR; VEGFR; mTOR; c-MET

向作者/读者索取更多资源

Background: Esophagogastric adenocarcinoma (EGC) is a molecular heterogeneous disease, and therefore, strategies with targeted therapy may be effective. Aim: This review will discuss phase Ill studies in advanced EGC concerning biologic agents targeting molecular pathways, such as EGFR, HER2, VEGFR, mTOR and c-MET. Results: HER2 inhibition with trastuzumab in combination with first line chemotherapy results in a significant survival benefit for HER2 positive carcinoma patients. Chemotherapy in combination with bevacizumab does not prolong survival in an unselected EGC patient cohort. Preliminary results of trials with EGFR, VEGFR and mTOR inhibitors are, thus far, disappointing in unselected patient cohorts. Promising studies in biomarker selected cohorts with HER2, EGFR and c-MET inhibitors are ongoing. Conclusion: Targeted therapy in EGC is emerging. Improved insight in the biologic background of EGC is needed to improve patient selection, combine agents and discover new targets and agents. This may improve outcome for metastasized EGC patients. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据